Is­rael's Im­mune Phar­ma waves the white flag af­ter fail­ing to se­cure deals for in­flam­ma­tion drug

An eosinophil reg­u­lat­ing drug that’s trav­eled down a wind­ing path to the clin­ic is once again set to switch hands.

Im­mune Phar­ma, which first in-li­censed bertil­i­mum­ab for im­muno­log­ic and in­flam­ma­to­ry dis­eases in 2011, has filed for Chap­ter 11 bank­rupt­cy via its US of­fice in New Jer­sey. Tony Fior­i­no, for­mer CEO of Brain­Storm Cell Ther­a­peu­tics, has been lead­ing the Is­raeli biotech ad in­ter­im since last Au­gust.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.